Revised Outcome.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fredun Pharmaceuticals reported strong FY2025-26 results with standalone revenue of Rs. 6,333.27 crore, up 40% from Rs. 4,517.06 crore in FY2024-25. Profit after tax grew 60% to Rs. 332.07 crore from Rs. 208.08 crore. The company received an unmodified (clean) audit opinion. Key board decisions include recommending a 7% final dividend (70 paise per share), approving a 2:1 bonus share issue, and increasing authorised share capital from Rs. 10 crore to Rs. 50 crore. Note 5 of financial results mentions one-time tax adjustments (deferred tax of Rs. 22.06 crore and short provision of Rs. 2.77 crore) related to prior years due to first-time MSME provision impact. The auditor's report flags a delay in IEPF transfers for unclaimed dividends from FY2015-16 to FY2017-18. Consolidated PAT stood at Rs. 326.21 crore vs Rs. 197.89 crore (65% growth).
The strong revenue and profit growth with clean audit opinion is positive for shareholders. The 2:1 bonus issue will triple the number of shares outstanding, diluting EPS but signaling management confidence. The IEPF compliance delay is a minor regulatory concern. Overall financial performance shows robust growth in the pharmaceutical business.